

LIQUID BIOPSY REQUISITION FORM

PATIENT INFORMATION (REQUIRED)

Name Last _____ First _____
Gender ☐ Male ☐ Female Date of Birth mm / dd / yyyy
Street _____
City _____ State _____ ZIP _____
MRN / Patient ID# _____
Phone# _____

SPECIMEN INFORMATION-LIQUID BIOPSY (REQUIRED)

Specimen ID _____
Collection date mm / dd / yyyy Time _____ ☐ AM ☐ PM
Sent date mm / dd / yyyy

A pathology report is required

PAXgene (blue top) specimen collection tubes and DeepSight collection kits must be utilized. Preferred minimum blood volume: > 20-30 ml. For additional details, please visit our website.

MOBILE PHLEBOTOMY REQUEST (ONCOLOGY OFFICE TO COMPLETE IF NEEDED)

Patient Phone (mobile preferred): _____
Patient Email (optional): _____
Patient Home Address: _____
City, ST, ZIP: _____

siParadigm Liquid Biopsy collection and shipping kit was provided to the patient.
Please fax this completed requisition, pathology report, and insurance information to **888-890-4774**

By completing this section, Client represents it has obtained patient's consent to be contacted by third-party service.

SPECIMEN INFORMATION - TISSUE BIOPSY (OPTIONAL)

Specimen ID _____ Block ID _____
Retrieval date from archive mm / dd / yyyy Sent date mm / dd / yyyy
Collection date mm / dd / yyyy Time _____ ☐ AM ☐ PM

FFPE block, or 4-10 of unstained slides, 5-micron thickness, shipped at room temperature. Minimum tissue area: at least 5 mm x 5 mm (preferred but not essential).

DIAGNOSIS (REQUIRED)

Date of Original Diagnosis
mm / dd / yyyy

BREAST

- ☐ Breast Carcinoma
☐ Other Breast Tumor

GENITOURINARY

- ☐ Prostate Adenocarcinoma
☐ Other Genitourinary Tumor

GYNECOLOGIC

- ☐ Endometrial Carcinoma
☐ Ovarian Carcinoma
☐ Other Gynecologic Tumor

LUNG

- ☐ Adenocarcinoma (NSCLC)
☐ Large Cell Carcinoma (NSCLC)
☐ Squamous Cell Carcinoma (NSCLC)
☐ Small Cell Lung Carcinoma
☐ Other Lung Tumor

GI

- ☐ Cholangiocarcinoma
☐ Colorectal Adenocarcinoma
☐ Gastric Adenocarcinoma
☐ Esophageal/Gastroesophageal Junction Adenocarcinoma
☐ Pancreatic Ductal Adenocarcinoma
☐ Pancreatic Neuroendocrine Tumor
☐ Other Gastrointestinal Tumor

SKIN

- ☐ Melanoma
☐ Other Skin Tumor _____

BRAIN

- ☐ Glioblastoma
☐ Other Brain Tumor _____

OTHER

- ☐ Carcinoma of Unknown Primary (CUP)
☐ Other _____

PHYSICIAN INFORMATION (REQUIRED)

Referring MD _____
Attending/Ordering MD _____
Account Information _____

THIRD-PARTY SPECIMEN LOCATION (REQUIRED)

Hospital/Facility _____ Phone # _____
Address _____
Fax # _____

BILLING INFORMATION (BOTH SIDES REQUIRED)

- | | |
|------------------------------------|---|
| <input type="checkbox"/> Insurance | SPECIMEN COLLECTION LOCATION |
| <input type="checkbox"/> Client | <input type="checkbox"/> Non-hospital/office patient |
| <input type="checkbox"/> Patient | <input type="checkbox"/> Out-patient hospital |
| | <input type="checkbox"/> In-patient hospital Discharge Date <u>mm</u> / <u>dd</u> / <u>yyyy</u> |

ICD-10 CODE _____

- ☐ Primary ☐ Metastatic If Metastatic, List primary _____
☐ Slides # _____ Unstained _____ Stained _____ ☐ H&E _____
☐ Paraffin Block(s) # _____ ☐ Choose best block
For global molecular/NGS testing only. Submit ≤4 FFPE blocks. Blocks will be combined for molecular testing when necessary.


A pathology report is required


Ⓜ Attach clinical notes, patient information, and insurance card (REQUIRED)

I am certified to order the test(s) listed below, such that these test(s) are medically necessary and I have obtained informed consent for the requested test(s) when pertinent.

Authorized Signature: _____ Date: _____

CONCURRENT LIQUID AND TISSUE TESTING OPTIONS

- ☐ **DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue**  **TAT 7-10 Days**
- On Liquid: DeepSight™ Comprehensive Liquid Biopsy (523 genes mutations and fusions)
 - On Tissue:
 - NGS (500+ genes, TMB, MSI)
 - HRD for PARPi therapy
 - IHC, FISH (as clinically pertinent and necessary)

- ☐ **DeepSight™ on Liquid +NGS 500-Genes on Tissue**  **TAT 7-10 Days**
- On Liquid: DeepSight™ Comprehensive Liquid Biopsy (523 genes mutations and fusions)
 - On Tissue:
 - NGS (500+ genes, TMB, MSI)
 - HRD for PARPi therapy

CONCURRENT SOMATIC AND GERMLINE TESTING OPTIONS

- ☐ **DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline)**

Concurrent ctDNA and Germline Reporting from Liquid Biopsy
For PARPi treatment: ☐ Breast ☐ Prostate ☐ Ovarian ☐ Pancreatic

LIQUID ONLY TESTING OPTIONS

- ☐ **DeepSight™ Comprehensive Liquid Biopsy**  **TAT 7-10 Days**
(523 genes mutations and fusions) including TMB and MSI

- ☐ **DeepSight™ Focused Liquid Biopsy**  **TAT 4-5 Days**
(50 genes mutations and fusions) Indicated only for lung, colon, and melanoma

REFLEX TESTING OPTIONS

- ☐ **Reflex Liquid to Tissue**
If liquid biopsy is negative or QNS reflex to siPortfolio Multi-Omics™ 500 genes testing on tissue

- ☐ **Reflex Tissue to Liquid**
If the tissue is unattainable in 3 working days reflex to DeepSight™ Comprehensive 523 genes liquid biopsy testing on liquid

INDIVIDUAL TESTS

- ☐ **HRD Germline on Liquid** **Tissue Biopsy Block is REQUIRED**
- | | | | |
|--|--|--|--|
| <input type="checkbox"/> PD-L1, SP263, FDA
<small>IMFINZI®</small> | <input type="checkbox"/> PD-L1, 22C3, FDA (DEFAULT)
<small>KEYTRUDA®</small> | <input type="checkbox"/> PD-L1, SP142, FDA
<small>TECENTRIQ®</small> | <input type="checkbox"/> PD-L1, 28-8, FDA
<small>OPDIVO®</small> |
|--|--|--|--|

PHYSICIAN (REQUIRED FOR GERMLINE TESTING ONLY)

Confirmation of Informed Consent & Statement of Medical Necessity:

I affirm each of the following: 1) I have provided genetic testing information to the patient and the patient has consented to such testing. 2) Testing is medically necessary for the diagnosis of a disease or syndrome. 3) The results will be used in the patient's medical management and treatment decisions. 4) The person listed as the ordering physician is authorized by law to order the test(s) requested herein.

Signature *(MANDATORY FOR TESTING – Results will be delayed if consent signature is missing) _____ Date _____

PATIENT/LEGAL GUARDIAN (REQUIRED FOR GERMLINE TESTING ONLY)

- Consent: I give permission to Neovare by siParadigm to perform genetic testing as requested by my physician. In the event that one of the following apply.

- I do not have health insurance - **Attach Check**
- I do not qualify for testing based on nationally recognized clinical criteria for medical necessity for hereditary cancer testing - **Attach Check**
- I do not qualify for testing based on my insurance company's medical necessity policy for hereditary cancer testing and will be responsible to make payment of \$250.00 upon receipt of bill

- I authorize Neovare by siParadigm to perform testing to determine my risk for hereditary cancer AND I understand that I will personally pay \$250.00 out of pocket for testing (to include extra shipping and handling) for these services.

***This self pay rate is NOT available to those patients with Medicare/Medicaid due to governmental guidelines.

Signature *(MANDATORY FOR TESTING – Results will be delayed if consent signature is missing) _____ Date _____

NEOVARE PORTFOLIO

APC, CDH1, MLH1, PALB2, RET, ATM, CDK4, MRE11A, PDGFRA, SDHA, AXIN2, CDKN2A, MSH2, PMS2, SDHB, BAP1, CHEK2, MSH3, POLD1, SDHC, BARD1, EPCAM, MSH6, POLE, SDHD, BMPR1A, HOXB13, MUTYH, PTEN, SMAD4, BRIPI, KIT, NBN, RAD50, STK11, BRCA1, MEN1, NFI, RAD51C, TP53, BRCA2, MITF, NTHL1, RAD51D, VHL.

523 GENE COMPREHENSIVE PANEL (LIQUID BIOPSY)

*ABL1, ABL2, ACVR1, ACVR1B, AKT1, **AKT2**, AKT3, ***ALK**, ALOX12B, ANKRD11, ANKRD26, APC, **AR**, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, **ATM**, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BBC3, BCL10, BCL2, BCL2L1, BCL2L11, BCL2L2, BCL6, BCOR, BCORL1, *BCR, BIRC3, BLM, BMPR1A, ***BRAF**, **BRCA1**, **BRCA2**, BRD4, BRIPI, BTG1, BTK, C11orf30, CALR, CARD11, CASP8, CBF, CBL, **CCND1**, CCND2, **CCND3**, **CCNE1**, CD274 (PD-L1), CD276, *CD74, CD79A, CD79B, CDC73, CDH1, CDK12, **CDK4**, **CDK6**, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CENPA, CHD2, CHD4, **CHEK1**, **CHEK2**, CIC, CREBBP, CRKL, CRLF2, CSF1R, CSF3R, CSNK1A1, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CUX1, CXCR4, CYLD, DAXX, DCUN1D1, DDR2, DDX41, DHX15, DICER1, DIS3, DNAJB1, DNMT1, DNMT3A, DNMT3B, DOT1L, E2F3, EED, EGFL7, *EGFR, EIF1AX, EIF4A2, EIF4E, EML4, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, **ERBB2 (HER2)**, **ERBB3**, ERBB4, **ERCC1**, **ERCC2**, ERCC3, ERCC4, ERCC5, ERG, ERFF1, **ESR1 (ER)**, ETS1, *ETV1, *ETV4, ETV5, *ETV6, *EWSR1, EZH2, FAM123B (AMER1), FAM175A, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FAS, FAT1, FBXW7, **FGF1**, **FGF10**, **FGF14**, **FGF19**, **FGF2**, **FGF23**, **FGF3**, **FGF4**, **FGF5**, **FGF6**, **FGF7**, **FGF8**, **FGF9**, **FGFR1**, ***FGFR2**, ***FGFR3**, **FGFR4**, FH, FLCN, FLI1, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FOXP1, FRS2, FUBP1, FYN, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GEN1, GID4, GLI1, GNAI1, GNAI3, GNAQ, GNAS, GPR124, GPS2, GREM1, GRIN2A, GRM3, GSK3B, H3F3A, H3F3B, H3F3C, HGF, HIST1H1C, HIST1H2BD, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3A, HIST2H3C, HIST2H3D, HIST3H3, HLA-A, HLA-B, HLA-C, HNF1A, HNRNP, HOXB13, HRAS, HSD3B1, HSP90AA1, ICOSLG, ID3, IDH1, IDH2, IFNGR1, IGF1, IGF1R, IGF2, IKBKE, IKZF1, IL10, IL7R, INHA, INHBA, INPP4A, INPP4B, INSR, IRF2, IRF4, IRS1, IRS2, JAK1, **JAK2**, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIF5B, **KIT**, KLF4, KLHL6, KMT2B, KMT2C, KMT2D, **KRAS**, **LAMP1**, LATS1, LATS2, LMO1, LRP1B, LYN, LZTR1, MAGI2, MALT1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, MAP3K13, MAP3K14, MAP3K4, MAPK1, MAPK3, MAX, MCL1, MDC1, **MDM2**, **MDM4**, MED12, MEF2B, MEN1, ***MET**, MGA, MITF, MLH1, MLL (KMT2A), MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MST1, MST1R, MTOR, MUTYH, MYB, **MYC**, **MYCL1**, **MYCN**, MYD88, MYO1, *NAB2, NBN, NCOA3, NCOR1, NEGR1, NFI, NF2, NFE2L2, NFKB1A, NKX2-1, NKX3-1, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, **NRAS**, **NRG1**, NSD1, *NTRK1, *NTRK2, *NTRK3, NUP93, *NUTM1, PAK1, PAK3, PAK7, PALB2, PARK2, PARP1, *PAX3, PAX5, PAX7, *PAX8, PBRM1, PDCD1, PDCD1LG2, **PDGFRA**, **PDGFRB**, PDK1, PDPK1, PGR, PHF6, PHOX2B, PIK3C2B, PIK3C2G, PIK3C3, **PIK3CA**, **PIK3CB**, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIM1, PLCG2, PLK2, PMAIP1, PMS1, PMS2, PNRC1, POLD1, POLE, *PPARG, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, **PTEN**, PTPN11, PTPRD, PTPRS, PTPRT, QKI, RAB35, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, **RAF1**, RANBP2, RARA, RASA1, RB1, RBM10, RECQL4, REL, ***RET**, RFW2, RHEB, RHOA, **RICTOR**, RIT1, RNF43, *ROS1, RPS6KA4, **RPS6KB1**, RPS6KB2, RPTOR, RUNX1, RUNX1T1, RYBP, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH2B3, SH2D1A, SHQ1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCD1, SMC1A, SMC3, SMO, SNCAIP, SOCS1, SOX10, SOX17, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, SRSF2, STAG1, STAG2, STAT3, STAT4, STAT5A, STAT5B, STK11, STK40, SUFU, SUZ12, SYK, TAFI, TBX3, TCEB1, TCF3, TCF7L2, **TERC**, TERT, TET1, TET2, *TFE3, TFRC, TGFB1, TGFB2, TMEM127, *TMPRSS2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TP63, TRAF2, TRAF7, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, VTCN1, WISP3, WTI, XIAP, XPO1, XRCC2, YAP1, YES1, ZBTB2, ZBTB7A, ZFXH3, ZNF217, ZNF703, ZRSR2.

Bold = Copy number variants (59)

* = Genes targeted for DNA based fusion detection

50 GENE FOCUSED PANEL (LIQUID BIOPSY)

AKT1, AKT2, AKT3, ***ALK**, ***AR**, ARAF, ***BRAF**, **CD274**, CDK4, **CDKN2A**, CHEK2, CTNNB1, ***EGFR**, **ERBB2**, **ERBB3**, ERBB4, ***ESR1**, ***FGFR1**, ***FGFR2**, ***FGFR3**, **FGFR4**, FLT3, GNAI1, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, **KRAS**, MAP2K1, MAP2K2, ***MET**, MTOR, NRAS, ***NRG1**, *NTRK1, *NTRK2, *NTRK3, *NUTM1, PDGFRA, **PIK3CA**, **PTEN**, RAF1, ***RET**, *ROS1, *RSPO2, *RSPO3, SMO, TP53.

Bold = Copy number variants (14)

* = Genes targeted for RNA based inter-genetic fusion

= Genes targeted for RNA based intra-genetic fusion

Please see separate solid tumor requisition for solid tumor NGS test gene lists